AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29565769 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic movement (12% O2 with passive knee movement)
Number of subjects: 14
Study 29565769 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxic movement (21% O2 with passive knee movement)
Number of subjects: 14
Study 27419927 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality-based Bilateral Upper Extremity Training (VRBT)
Number of subjects: 18
Study 27419927 — intervention group
Group type: COMPARATOR
Intervention: Bilateral Upper Limb Training (BT)
Number of subjects: 18
Study 25644584 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal arm (11 patients)
Number of subjects: 17
Study 23053376 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine infiltration to peritonsillary fossae prior to surgery
Number of subjects: 40
Study 23053376 — intervention group
Group type: COMPARATOR
Intervention: Control group with no medication
Number of subjects: 40
Study 20724185 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT preparation (2 mg 17β-estradiol, E₂; 1 mg norethisterone acetate, NETA)
Number of subjects: 19
Study 20724185 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 19
Study 20724185 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT preparation (E₂ or NETA)
Number of subjects: 19
Study 20724185 — intervention group
Group type: EXPERIMENTAL
Intervention: NETA
Number of subjects: 19
Study 20724185 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT preparation
Number of subjects: 19
Study 17995980 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy (T)
Number of subjects: 60
Study 17995980 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin‐C (TMMC)
Number of subjects: 60
Study 17995980 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with ePTFE (TG)
Number of subjects: 60
Study 17995980 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin‐C and ePTFE (TGMMC)
Number of subjects: 60
Study 17995980 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE usage
Number of subjects: 60
Study 17995980 — intervention group
Group type: COMPARATOR
Intervention: Groups without ePTFE
Number of subjects: 60
Study 17995980 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin-C application
Number of subjects: 60
Study 16645441 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocytes stored for less than 5 hours (fresh)
Number of subjects: 9
Study 16645441 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocytes stored for 3 weeks (stored)
Number of subjects: 9
Study 12803592 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular saline 10 ml
Number of subjects: 40
Study 12803592 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular saline 10 ml with morphine 2 mg
Number of subjects: 40
Study 10937399 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promoting schools intervention (seminars, training, resource kit, support network)
Number of subjects: 22
Study 10937399 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 22
Study 10937399 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promoting schools intervention
Number of subjects: 22
Study 8626357 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 318
Study 8626357 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 318
Study 1473916 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic agent alteplase
Number of subjects: 31
Study 6464192 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz 2 X 20 mg/kg
Number of subjects: 158
Study 6464192 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel 2 X 30 mg/kg
Number of subjects: 158
Study 6464192 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz 1 X 25 mg/kg
Number of subjects: 158
Study 6464192 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz 1 X 35 mg/kg
Number of subjects: 158
Study 31381847 — intervention group
Group type: EXPERIMENTAL
Intervention: CRA‐melatonin (5 mg)
Number of subjects: 10
Study 31381847 — intervention group
Group type: COMPARATOR
Intervention: IR‐melatonin (5 mg)
Number of subjects: 10
Study 29779247 — intervention group
Group type: EXPERIMENTAL
Intervention: POLLINEX® Quattro Plus 1.0 ml Birch 100% (cumulative doses ranging from 5100 to 27300 SU)
Number of subjects: 0
Study 29779247 — intervention group
Group type: EXPERIMENTAL
Intervention: POLLINEX® Quattro Plus 1.0 ml Birch 100% (highest cumulative dose of 27300 SU)
Number of subjects: 0
Study 29779247 — intervention group
Group type: EXPERIMENTAL
Intervention: POLLINEX® Quattro Plus 1.0 ml Birch 100% (various active doses)
Number of subjects: 0
Study 29779247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27658879 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing and counselling plus a social network intervention
Number of subjects: 1200
Study 27658879 — intervention group
Group type: COMPARATOR
Intervention: Testing and counselling (control group)
Number of subjects: 1200
Study 24990024 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 14
Study 24990024 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 14
Study 22265052 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginoscopic hysteroscopy using the H Pipelle
Number of subjects: 90
Study 22265052 — intervention group
Group type: COMPARATOR
Intervention: Traditional hysteroscopy using the standard Pipelle
Number of subjects: 90
Study 22265052 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 90
Study 22265052 — intervention group
Group type: EXPERIMENTAL
Intervention: H Pipelle
Number of subjects: 90
Study 20537866 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 13
Study 20537866 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic patients with schizophrenia (mean duration of illness 7.6 years)
Number of subjects: 13
Study 20537866 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study 18852657 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (B)
Number of subjects: 47
Study 18852657 — intervention group
Group type: COMPARATOR
Intervention: Steroids (S)
Number of subjects: 47
Study 18852657 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (B) in hepatitis C virus patients
Number of subjects: 47
Study 18852657 — intervention group
Group type: COMPARATOR
Intervention: Steroids (S) in hepatitis C virus patients
Number of subjects: 47
Study 15894284 — intervention group
Group type: EXPERIMENTAL
Intervention: Main line ballast
Number of subjects: 5
Study 15894284 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking ballast
Number of subjects: 5
Study 15894284 — intervention group
Group type: COMPARATOR
Intervention: Level concrete
Number of subjects: 5
Study 12051959 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) at a dose of 2 g/day
Number of subjects: 0
Study 12051959 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) at a dose of 4 g/day
Number of subjects: 0
Study 12051959 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 0
Study 10192648 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma C-reactive protein (CRP) levels
Number of subjects: 834
Study 10192648 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels at or above the 97.5th centile (6.17 mg/L)
Number of subjects: 834
Study 10192648 — intervention group
Group type: EXPERIMENTAL
Intervention: Log CRP levels
Number of subjects: 834
Study 10192648 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels at or above the 85th, 90th, and 95th percentiles
Number of subjects: 834
Study 7730940 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-coordinated intervention (telephone contacts at least monthly)
Number of subjects: 275
Study 7730940 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 275
Study 2292537 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous ciprofloxacin
Number of subjects: 42
Study 7000346 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF (cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 69
Study 7000346 — intervention group
Group type: COMPARATOR
Intervention: CAMP (CCNU, melphalan, methotrexate, and prednisone)
Number of subjects: 69
Study 31814431 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - Kinesio tape (KT) applied
Number of subjects: 40
Study 31814431 — intervention group
Group type: COMPARATOR
Intervention: Placebo Group (PG) - Placebo KT applied
Number of subjects: 40
Study 30739617 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain from 6 to 12 months of age
Number of subjects: 650
Study 30739617 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain during the 0- to 6-month period
Number of subjects: 650
Study 30739617 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain during the periods of 6-12 months and 18-24 months of age
Number of subjects: 650
Study 28800861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib 400 mg once per day (days 1-21) plus intravenous paclitaxel 80 mg/m2 (days 1, 8, 15)
Number of subjects: 124
Study 28800861 — intervention group
Group type: COMPARATOR
Intervention: Placebo once per day (days 1-21) plus intravenous paclitaxel 80 mg/m2 (days 1, 8, 15)
Number of subjects: 124
Study 28800861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib 400 mg once per day (days 1-21) plus intravenous paclitaxel 80 mg/m2 (days 1, 8, 15) in PTEN-low population
Number of subjects: 124
Study 28800861 — intervention group
Group type: COMPARATOR
Intervention: Placebo once per day (days 1-21) plus intravenous paclitaxel 80 mg/m2 (days 1, 8, 15) in PTEN-low population
Number of subjects: 124
Study 28800861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Number of subjects: 124
Study 28800861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 25457470 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA (100 mg/Kg loading dose over 20 minutes, followed by 10 mg/Kg/h until skin closure)
Number of subjects: 59
Study 25457470 — intervention group
Group type: COMPARATOR
Intervention: Control (saline infusion of similar volume)
Number of subjects: 59
Study 22595491 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified biscuits
Number of subjects: 0
Study 22595491 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient intakes (iron and folate)
Number of subjects: 0
Study 22595491 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthelmintic treatment
Number of subjects: 0
Study 22182286 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhoods with high poverty (highest tertile)
Number of subjects: 1010
Study 22182286 — intervention group
Group type: COMPARATOR
Intervention: Neighborhoods with low poverty (lowest tertile)
Number of subjects: 1010
Study 19755194 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer positioned before the heat humidification system (group 1, n = 19)
Number of subjects: 38
Study 19755194 — intervention group
Group type: COMPARATOR
Intervention: Nebulizer positioned at the end of the inspiratory limb before the Y‐piece (group 2, n = 19)
Number of subjects: 38
Study 17095879 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical apraclonidine 0.5%
Number of subjects: 78
Study 17095879 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetazolamide
Number of subjects: 78
Study 17095879 — intervention group
Group type: COMPARATOR
Intervention: No hypotensive treatment (control group)
Number of subjects: 78
Study 14998429 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter intervention advising to start a BPLD
Number of subjects: 8592
Study 14998429 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter intervention advising to start a LLD
Number of subjects: 8592
Study 14998429 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 8592
Study 14998429 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of BPLD use
Number of subjects: 8592
Study 14998429 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of LLD use
Number of subjects: 8592
Study 11699680 — intervention group
Group type: EXPERIMENTAL
Intervention: depo-testosterone (males)
Number of subjects: 56
Study 11699680 — intervention group
Group type: EXPERIMENTAL
Intervention: conjugated estrogens (females)
Number of subjects: 56
Study 9737833 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextranomer paste
Number of subjects: 23
Study 9737833 — intervention group
Group type: COMPARATOR
Intervention: Saline dressings
Number of subjects: 23
Study 7801083 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened i.v. treatment duration (1-3 days)
Number of subjects: 0
Study 7801083 — intervention group
Group type: EXPERIMENTAL
Intervention: Infections of the lower respiratory tract
Number of subjects: 0
Study 7801083 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary tract infections
Number of subjects: 0
Study 3137626 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipequaline 50 mg
Number of subjects: 12
Study 3137626 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipequaline 150 mg
Number of subjects: 12
Study 3137626 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 12
Study 3137626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3137626 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipequaline 50 mg + Diazepam 10 mg
Number of subjects: 12
Study 3137626 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipequaline 150 mg + Diazepam 10 mg
Number of subjects: 12
Study 30980922 — intervention group
Group type: EXPERIMENTAL
Intervention: Free weights training (FWT)
Number of subjects: 32
Study 30980922 — intervention group
Group type: COMPARATOR
Intervention: Machine training (MT)
Number of subjects: 32
Study 26990963 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid group (inhaled with Seretide/Pulmicort)
Number of subjects: 133
Study 26990963 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid group
Number of subjects: 133
Study 27301362 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertility education (intervention group)
Number of subjects: 1455
Study 27301362 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (intake of folic acid during pregnancy)
Number of subjects: 1455
Study 27301362 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (governmental financial support for pregnancy and childbirth)
Number of subjects: 1455
Study 24531600 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual instruction (motivation) provided every weekend for 12 weeks in the study group.
Number of subjects: 372
Study 24531600 — intervention group
Group type: COMPARATOR
Intervention: Control group without motivation.
Number of subjects: 372
Study 22855392 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (5 mg once a day for 4 days)
Number of subjects: 304
Study 22855392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 21287803 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 38
Study 21287803 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Cosopt)
Number of subjects: 38
Study 21287803 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin analogues
Number of subjects: 38
Study 21287803 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonic anhydrase inhibitors (CAI)
Number of subjects: 38
Study 21287803 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-2 agonists
Number of subjects: 38
Study 18047000 — intervention group
Group type: EXPERIMENTAL
Intervention: epi‐LASIK
Number of subjects: 16
Study 18047000 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 16
Study 16566363 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive system (TCS) with 20 microg ethinyl estradiol (EE) and 150 microg norelgestromin (17‐dNGM)
Number of subjects: 20
Study 16566363 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive containing 20 microg EE and 150 microg desogestrel
Number of subjects: 20
Study 11069322 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 1 mg/day
Number of subjects: 19
Study 11069322 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 4 mg/day
Number of subjects: 19
Study 11069322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11069322 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 1 mg/day and 4 mg/day
Number of subjects: 19
Study 9283504 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 51
Study 9283504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 8117608 — intervention group
Group type: EXPERIMENTAL
Intervention: P-100 administered for ten days following chemotherapy during the first cycle
Number of subjects: 26
Study 8117608 — intervention group
Group type: EXPERIMENTAL
Intervention: P-100 administered for ten days following chemotherapy during the second cycle
Number of subjects: 26
Study 8117608 — intervention group
Group type: COMPARATOR
Intervention: P-100
Number of subjects: 26
Study 3088860 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (35 micrograms b.i.d.)
Number of subjects: 97
Study 3088860 — intervention group
Group type: COMPARATOR
Intervention: Pirenzepine
Number of subjects: 97
Study 3088860 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 97
Study 3397493 — intervention group
Group type: EXPERIMENTAL
Intervention: Seiko P-3 progressive addition lenses
Number of subjects: 40
Study 3397493 — intervention group
Group type: COMPARATOR
Intervention: Varilux 2 progressive addition lenses
Number of subjects: 40
Study 31099455 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief informative phone call prior to receiving the standard screening invitation
Number of subjects: 512
Study 31099455 — intervention group
Group type: COMPARATOR
Intervention: Standard screening invitation alone
Number of subjects: 512
Study 28695570 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 16
Study 28695570 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly mass drug administration of dihydroartemisinin-piperaquine
Number of subjects: 16
Study 28695570 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimonthly mass drug administration of dihydroartemisinin-piperaquine
Number of subjects: 16
Study 28695570 — intervention group
Group type: EXPERIMENTAL
Intervention: Single low dose of primaquine added to DHA-piperaquine treatment
Number of subjects: 16
Study 25255776 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine treatment
Number of subjects: 494
Study 23811659 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine
Number of subjects: 80
Study 23811659 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium hypochlorite
Number of subjects: 80
Study 23811659 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hydrogen peroxide
Number of subjects: 80
Study 23811659 — intervention group
Group type: COMPARATOR
Intervention: No cavity disinfectant (Control)
Number of subjects: 80
Study 21428765 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 μg once daily)
Number of subjects: 7376
Study 21428765 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (50 μg twice daily)
Number of subjects: 7376
Study 19880464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy (CET)
Number of subjects: 58
Study 19880464 — intervention group
Group type: COMPARATOR
Intervention: Enriched Supportive Therapy (EST)
Number of subjects: 58
Study 16242903 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping-enhancing experimental group (n=59)
Number of subjects: 106
Study 16242903 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard care (n=47)
Number of subjects: 106
Study 15006588 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient geriatric clinic care
Number of subjects: 834
Study 15006588 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient geriatric unit care
Number of subjects: 834
Study 11383756 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 12 weeks (T12)
Number of subjects: 0
Study 11383756 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 16 weeks (T16)
Number of subjects: 0
Study 11383756 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 400 mg/day for 1 week in every 4 weeks for 12 weeks (I3)
Number of subjects: 0
Study 11383756 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 400 mg/day for 1 week in every 4 weeks for 16 weeks (I4)
Number of subjects: 0
Study 9164215 — intervention group
Group type: COMPARATOR
Intervention: 5-FU alone
Number of subjects: 1696
Study 9164215 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU with leucovorin
Number of subjects: 1696
Study 9164215 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU with levamisole
Number of subjects: 1696
Study 9164215 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU with leucovorin and levamisole
Number of subjects: 1696
Study 12959310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12959310 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg
Number of subjects: 20
Study 12959310 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 5 mg
Number of subjects: 20
Study 12959310 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ramipril 2.5 mg and felodipine ER 5 mg
Number of subjects: 20
Study 3303792 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole 10 mg
Number of subjects: 0
Study 3303792 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole 40 mg
Number of subjects: 0
Study 3303792 — intervention group
Group type: COMPARATOR
Intervention: Thyroid hormone supplementation
Number of subjects: 0
Study 30820567 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drink (sustained breath alcohol concentration = .08)
Number of subjects: 42
Study 30820567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 31606032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified home screening and linkage for TB and HIV intervention
Number of subjects: 0